This is an aggregated industry headline. Read the full story at BioPharma Dive →
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
By BioPharma Dive
· Jun 15, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Following criticism from drugmakers, Germany has scrapped its plan to install a program that would have reduce…
The WeekFierceBiotech ↗
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients' Robart's Histopathology…
The WeekBriefing
The FDA approved Colorado’s proposal to import certain Canadian drugs, aiming to curb costs for state resident…